Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Walgreens Boots Alliance Nearly Halves Dividend To Strengthen Balance Sheet, Reports Better Than Expected Q1 Earnings

Published 04/01/2024, 15:27
Updated 04/01/2024, 16:40
© Reuters.  Walgreens Boots Alliance Nearly Halves Dividend To Strengthen Balance Sheet, Reports Better Than Expected Q1 Earnings

Benzinga - by Vandana Singh, Benzinga Editor.

Walgreens Boots Alliance Inc's (NASDAQ: WBA) Q1 FY24 sales increased 10% Y/Y to $36.7 billion, up 8.7% on a constant currency basis, beating the consensus of $34.86 billion.

Adjusted operating income was $687 million, down 33% Y/Y on a constant currency basis, reflecting softer U.S. retail market trends, partly offset by improved profitability in U.S. Healthcare and International growth.

Adjusted EPS decreased 43.1% to $0.66, beating the consensus of $0.61, according to data from Benzinga Pro.

Walgreens' U.S. retail pharmacy segment generated $28.9 billion in sales, up 6.4%. Comparable sales at individual locations rose 8.1%.

Total prescriptions filled in the quarter, including immunizations, adjusted to 30-day equivalents was 311.6 million, which was flat compared to the prior year.

Dividends: Walgreens also reduced its quarterly dividends by 48% to 25 cents per share, payable on March 12, 2024, to stockholders of record as of February 20, 2024.

"We have made the difficult decision to reduce our quarterly dividend payment to 25 cents per share to strengthen our long-term balance sheet and cash position," said CEO Tim Wentworth.

Walgreens Boots Alliance maintains FY24 adjusted EPS of $3.20-$3.50 compared to the consensus of $3.33, down from $3.98 in FY23.

The company expects U.S. Healthcare adjusted EBITDA to be breakeven at the midpoint of the guidance range of ($50) to $50 million.

Price Action: WBA shares are down 9.80% at $23.07 on the last check Thursday.

Photo via Wikimedia Commons

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.